|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||76.54 - 78.31|
|52 Week Range||52.83 - 80.19|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||62.44|
|Earnings Date||Jan 31, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||2.20 (2.87%)|
|1y Target Est||80.07|
McDonald's Corp said on Tuesday it plans to reduce the use of antibiotics in its global beef supply, fueling projections that other restaurants will follow suit. The move by the world's biggest fast-food chain addresses concerns that the overuse of antibiotics vital to fighting human infections in farm animals may diminish the drugs' effectiveness in people. McDonald's becomes the biggest beef buyer to tackle the issue in cattle, potentially creating a new standard for livestock producers and threatening sales by drug companies such as Merck & Co and Elanco Animal Health.
Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.
Clovis Oncology Inc (NASDAQ: CLVS ) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK )'s proposed acquisition of TESARO Inc (NASDAQ: TSRO ), according to Gabelli Research. ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...
Merck (MRK), known as MSD outside the United States and Canada, today announced that Adam H. Schechter, president of Global Human Health (GHH), is stepping down from his current position as of Dec. 31, 2018, and will be shifting to an advisory capacity to the CEO. The company is taking the opportunity to reshape its commercial organization and is creating two new Executive Committee roles. Frank Clyburn has been promoted to Chief Commercial Officer and Michael Nally has been promoted to Chief Marketing Officer.
Pfizer (NYSE:PFE) may find itself doing something it has not done in years—break records. The New York-based pharmaceutical giant found itself stuck as PFE stock spent years mired in a trading range. Now it looks poised to reach and surpass the highs that have eluded Pfizer for almost two decades.
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.
Despite the volatile market, these 16 stocks to watch are showing relative strength and may pop if the stock market rebounds.
The " Fast Money " traders shared their first moves for the market open. Pete Najarian was a buyer of Merck MRK . Tim Seymour was a buyer of Boeing BA . Dan Nathan was a buyer of Disney DIS . Guy Adami was a buyer of Twitter TWTR .
Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity with excellent safety and tolerability in advanced breast cancer patients.
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
“In health care alone, there are massive amounts of unstructured data generated every day in labs,” Michael Vande Vrede, head of digital products at Merck KGaA, said Tuesday at the conference on Neural Information Processing Systems (NeurIPS) in Montreal, where the two companies announced their collaboration. V7 has created software called Graphotate that makes it easier and faster to annotate scientific imagers and videos.